Author:
Ross Sharona B.,Sucandy Iswanto,Trotto Michael,Christodoulou Maria,Pattilachan Tara M.,Jattan Jenna,Rosemurgy Alexander S.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Luberice K, Ross S, Crespo K, De La Cruz C, Dolce J-K, Sucandy I, Rosemurgy AS (2021) Robotic complex fundoplication in patients at high-risk to fail. JSLS 25(e2020):00111. https://doi.org/10.4293/JSLS.2020.00111
2. Rosemurgy AS, Donn N, Paul H, Luberice K, Ross SB (2011) Gastroesophageal reflux disease. Surg Clin N Am 91:1015–1029. https://doi.org/10.1016/j.suc.2011.06.004
3. US Food and Drug Administration (2010) FDA drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump. Accessed 10 Nov 2023
4. Roark R, Sydor M, Chatila AT, Umar S, Guerra RDL, Bilal M, Guturu P (2020) Management of gastroesophageal reflux disease. Dis Mon 66:100849. https://doi.org/10.1016/j.disamonth.2019.02.002
5. Dean BB, Gano AD, Knight K, Ofman JJ, Fass R (2004) Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2:656–664. https://doi.org/10.1016/S1542-3565(04)00288-5